Cinfa: Leveraging
prevention for better
hypertension outcomes in the
MENA region
(MIDDLE EAST)
-
A
silent condition that can
quietly damage lives,
hypertension affects more
than one billion people
worldwide, one in four
adults, and fewer than one
in five have their condition
under control. The situation
is particularly pressing in
the Middle East and North
Africa (MENA). Across the
region, nearly 30% of adults
are living with high blood
pressure, often without
knowing it. In the UAE,
28.8% of adults are
hypertensive, and other
countries report similar
numbers: 29–30% in Saudi
Arabia, Egypt, and Jordan,
25.3% in Kuwait, and 22.8%
in Qatar.
Prevention Starts with the
Patient
With
a strong commitment to
cardiovascular health and
other key areas,
Cinfa is
contributing to improved
healthcare through its
growing presence in the MENA
region. The company offers a
wide range of accessible,
high-quality cardiovascular
medicines, including
treatments for hypertension,
high cholesterol, and heart
failure. Most recently,
Cinfa expanded its
cardiovascular portfolio
with the launch of Olmedine
HCT and Vanguard CCB Plus,
both currently available in
the UAE. Olmedine HCT is
used as a treatment for
adult patients whose blood
pressure is insufficiently
controlled. The use of
Olmedine HCT is a rational
approach to achieve optimal
therapeutic benefits by
minimizing tablet burden,
which is especially
important in chronic
diseases such as
hypertension. Vanguard CCB
Plus helps control high
blood pressure.
According to Dr.
Alicia López de Ocáriz,
Corporate Medical Director
at Cinfa,
“preventing and controlling
cardiovascular conditions
should be a shared priority
among patients,
professionals, and
institutions.” She noted
that “at Cinfa, our approach
goes beyond treatment. We
believe in supporting early
diagnosis, raising
awareness, and helping
patients adhere to long-term
therapies.”
This
includes working with local
healthcare providers,
supporting medical
education, and helping
clinicians simplify
treatments to improve
adherence.
Guidelines for Hypertension
Management: Why Is It
Important to Control Blood
Pressure?
Hypertension is often driven
by sedentary lifestyles,
obesity, high salt intake,
and low awareness. Many
people live with the
condition undiagnosed, and
even among those receiving
treatment, control remains a
challenge. According to WHO
estimates, only 20% of
patients have their blood
under control globally and,
in the MENA region, this
figure drops to just 16%, a
gap that claims the need for
localized prevention and
management strategies.
In this regard, Cinfa
emphasizes the importance of
reinforcing prevention
efforts. “We know that over
50% of cardiovascular events
are linked to modifiable
risk factors,” López de
Ocáriz pointed out7. “That
gives us a real chance to
prevent disease, not just
treat it”. One first step
could be to examine the
blood pressure guidelines
established by the European
Society of Cardiology to
better understand the risks
associated with hypertension
and treat them. The
diagnosis of hypertension
and elevated BP requires
confirmation using
out-of-office measurements
(HBPM or ABPM) or at least
one additional subsequent
office measurement.
Blood Pressure Classification
|
|
Non-elevated blood pressure
|
Elevated blood pressure
|
Hypertension
|
Office BP
|
SBP <120 mmHg and
DBP <70 mmHg
|
SBP 120–139 mmHg or
DBP 70–89 mmHg
|
SBP ≥140 mmHg or DBP
≥90 mmHg
|
HBPM
|
SBP <120 mmHg and
DBP <80 mmHg
|
SBP 120–134 mmHg and
DBP 80–84 mmHg
|
SBP ≥135 mmHg and
DBP ≥85 mmHg
|
ABPM
|
Daytime SBP <120
mmHg and DBP <70
mmHg
|
Daytime SBP 120–134
mmHg and DBP 70–84
mmHg
|
Daytime SBP ≥135
mmHg and DBP ≥85
mmHg
|
Recommendations for
pharmacological
treatment
|
Insufficient
evidence confirming
the efficacy and
safety of BP
pharmacological
treatment
|
Risk stratifies to
identify individuals
with high
cardiovascular risk
for BP
pharmacological
treatment
|
Cardiovascular risk
is sufficiently high
to merit BP
pharmacological
treatment initiation
|
BP = blood
pressure; SBP =
systolic blood pressure; DBP = diastolic blood pressure;
HBPM = home blood pressure
monitoring;
ABPM = ambulatory blood pressure
monitoring.
Working Hand in
Hand with Healthcare
Professionals to Transform
Heart Health in the Region
To support the
challenges in cardiovascular
care, Cinfa collaborates
with medical societies,
hospitals and healthcare
professionals across MENA.
The company also takes part
in key scientific events
such as the Annual
Conference of the Saudi
Heart Association,
supporting local dialogue
and strategies for heart
health. “Our presence in the
region goes far beyond the
supply of medicines”, says
Franc Vives, Chief
International Officer at
Cinfa Group. “We
are committed to working
alongside healthcare
professionals, institutions
and communities to reduce
barriers and create
sustainable access to
cardiovascular care.”
REFERENCES:
1. World Heart Federation,
Hypertension
2. Ministry of Health UAE,
Hypertension
Prevalence 3.
Systematic review and meta-analysis:
Prevalence of hypertension
among adolescents in the
Arab countries. Published in
Journal of Pediatric
Nursing.
4.
Hypertension prevalence, awareness,
and control in Arab
countries: Systematic.
Published in Nursing &
Health Sciences.
Doi:
10.1111/nhs.12060
5.
WHO:
Hypertension Key Facts
6.
WHO EMR –
World Hypertension Day
2024 7. 2024 ESC Guidelines for the
management of elevated blood
pressure and hypertension.
PRINT
THIS ARTICLEfont>
|